Clinical Presentations of Leishmaniasis
Leishmaniasis presents in three main clinical forms: cutaneous (most common), mucosal, and visceral, each with distinct manifestations that depend on the infecting species, geographic acquisition, and host immune response. 1
Cutaneous Leishmaniasis (CL)
Classic Presentation
CL occurs in afebrile patients with a travel or residence history in endemic areas who develop one or more chronic skin lesions on exposed areas 1. The hallmark features include:
- Painless lesions (unless secondarily infected or over joints)
- Well-defined, indurated borders without purulence
- Chronicity developing over weeks to months
- Lesions begin as papules, enlarge, and typically ulcerate
- Incubation period: at least several weeks after sand fly bite 1
Morphologic Variations
Lesions may present as 1:
- Chronic ulcers (most common)
- Papules or nodules
- Verrucous (wart-like) lesions
- Plaques
- Crusted eschars (particularly L. tropica)
Associated Features
- Regional lymphadenopathy
- Sporotrichoid pattern: subcutaneous nodules along lymphatic drainage
- Satellite papules around primary lesion
- Lesions can occur at inoculation sites or distant trauma sites 1
Natural History by Species
Spontaneous healing occurs variably 1:
- L. major: 2-6 months
- L. mexicana: 3-9 months
- L. tropica, L. (V.) braziliensis, L. (V.) panamensis: 6-15 months
- Healing typically leaves residual scarring 1
Atypical Presentations
Recent literature documents numerous atypical forms 2, 3:
- Lupoid (leishmaniasis recidivans): recurrence around scar edges
- Erysipeloid, impetiginous, eczematous patterns
- Sporotrichoid: lymphatic spread pattern
- Diffuse cutaneous leishmaniasis (DCL): rare, severe form caused by L. mexicana, L. amazonensis, L. aethiopica 1
- Disseminated cutaneous leishmaniasis: multiple widespread lesions from L. (V.) braziliensis 1
Immunocompromised Patients
In HIV/AIDS or other immunosuppression, expect 1:
- Atypical, multifocal, pleomorphic lesions
- Nonulcerative, papulonodular forms
- Persistent, progressive, remitting-relapsing course
- Unusual distribution on skin and mucous membranes
- Risk of cutaneous, mucosal, and visceral dissemination 1
Mucosal Leishmaniasis (ML)
Key Clinical Features
ML develops as metastatic infection following or concurrent with New World CL, particularly from L. (V.) braziliensis and related Viannia species from Costa Rica southward 1.
Initial manifestations are predominantly nasal 1:
- Chronic unexplained nasal congestion
- Nasal secretions/discharge
- Epistaxis (nosebleeds)
- Chronic nasal stuffiness
Progressive Findings
As disease advances 1:
- Erythema, edema, hyperemia of mucosa
- Infiltration and nodules
- Erosion and ulceration
- Tissue destruction: septal perforation (pathognomonic finding)
- Oral/palatal, pharyngeal, laryngeal involvement
- Hoarseness (laryngeal involvement)
Critical Timing
Risk for ML is highest within 2 years of initial cutaneous lesion onset 1. ML can cause destructive, disfiguring lesions affecting nasal, oral, pharyngeal structures and airways, with difficult treatment outcomes 1.
Visceral Leishmaniasis (VL)
While the provided evidence focuses primarily on cutaneous and mucosal forms, VL is noted as:
- Potentially life-threatening requiring prompt treatment 1
- Involves dissemination throughout reticuloendothelial system
- Affects spleen and liver (Kala-azar) 1, 4
- Can present as opportunistic infection in immunocompromised hosts 1
Critical Clinical Pitfalls
Always Perform Naso-oropharyngeal Examination
Every patient with CL requires careful nasal and oropharyngeal examination at initial and follow-up visits, even without mucosal symptoms 1. This is non-negotiable for detecting early ML.
Geographic Risk Stratification
Determine region of acquisition to assess ML risk 1:
- High ML risk: Viannia species from Costa Rica southward, or unknown species from ML-endemic regions
- Low ML risk: Old World acquisition, or New World non-Viannia species, or Viannia from north of Costa Rica
Secondary Infection Mimicry
Purulence is NOT typical of CL unless secondarily infected 1. Suppurative or impetiginous appearance suggests bacterial superinfection requiring additional management.
Long-term Surveillance
Patients require monitoring for at least 1 year, or 2 years if high ML risk, with education about signs of relapse and ML 1. Even after surveillance ends, late ML remains possible 1.